ENGOT-ov51 / NItCHE

STATUS: Recruiting

SPONSOR: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
LEAD GROUP: MITO
ENGOT Model: B
TITLE: Randomized Phase III Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment. NItCHE Trial (MITO 33)
ClinicalTrials.gov ID: NCT04679064
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: AGO Study Group
LEAD GROUP: AGO
ENGOT Model: A
TITLE: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
ClinicalTrials.gov ID: NCT05009082
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: NOGGO
LEAD GROUP: NOGGO
ENGOT Model: B
TITLE: A Phase II randomized, open label, non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
ClinicalTrials.gov ID: NCT05460000
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: GINECO
LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery
ClinicalTrials.gov ID:  NCT05183984
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: ImmunoGen, Inc.
LEAD GROUP: MITO
ENGOT Model: A
TITLE:  Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
ClinicalTrials.gov ID: NCT05445778
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Daiichi Sankyo
LEAD GROUP: GINECO
ENGOT Model: C
TITLE: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
ClinicalTrials.gov ID: NCT06161025   
MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: European Cancer Patient Coalition

LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery.”
ClinicalTrials.gov ID: to be defined   
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Sutro Biopharma, Inc.
LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)
ClinicalTrials.gov ID: to be defined  
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Verastem, Inc.
LEAD GROUP: NCRI
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
ClinicalTrials.gov ID: NCT06072781
MaNGO Sites (click to see the list)

STATUS: Planned

LEAD GROUP: GINECO
ENGOT Model: C
TITLE: Rechallenge with PARPi in 1st platinum sensitive relapse for patients who received PARPi in 1st line but did not progressed under PARPi therapy
ClinicalTrials.gov ID: to be defined
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Merck Sharp & Dohme LLC

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
ClinicalTrials.gov ID: to be defined
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Merck Sharp & Dohme LLC

LEAD GROUP: GINECO
ENGOT Model: C
TITLE: Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinumbased Chemotheapy
ClinicalTrials.gov ID: to be defined
MaNGO Sites (click to see the list)